Sarcoma_ UK_chryso_kanthou
Principal Investigators: 
Award Amount: 
£38,319

Sarcomas are difficult to treat and there is an urgent need to develop more effective therapies. Like other cancers, sarcomas, develop blood vessels that ‘feed’ them with oxygen and nutrients, and allow their growth and spread.  Several drugs have been developed that specifically target and damage these blood vessels and some of these drugs are now being used to treat sarcoma. While some patients clearly benefit from this type of therapy others don’t, making it difficult to tailor treatments to the needs of individual patients.

More information is needed about the factors causing some sarcomas to respond to these drugs so a test can be developed that will predict patient response. Our project is an important step in this direction. Specially, we will look at two proteins produced by cancer cells, neuropilin-1 and VEGF. These proteins drive the development of tumour blood vessels and clinical trials have indicated they may be used to predict response to vessel targeting drugs such as Avastin.

We will use a panel of sarcoma cells developed in our laboratory to test molecular interactions between the two proteins. This will help us understand how either singly or together they influence tumour growth and response to Avastin or other vessel-targeting treatments. We will manipulate levels of these proteins in the cells we developed and in other sarcoma cells, and test them in our mouse models. Our results should establish whether these proteins have the potential to be developed as reliable markers to predict sarcoma patient response to vessel targeting drugs.

Outputs

Posters

  • Poster presented at The Medical School Annual Research Meeting at the University of Sheffield. June, 2016. Sheffield, UK.
  • Neuropilin-1 and VEGF isoforms as major players in soft tissue sarcoma response to vascular-targeted therapies. Poster presented at the Sarcoma Research Symposium. September, 2018. London, UK.
  • Thomas, R., Tozer, G. M. and Kanthou, C. Interactions of neuropilin-1 and VEGF isoforms in the development of vascular-targeted treatment strategies in soft tissue sarcoma. Poster presented at the 8th Conference on Experimental and Translational Oncology. April, 2017. Portoroz, Slovenia.
  • Thomas, R., Tozer, G. M. and Kanthou, C. Interactions of neuropilin-1 and VEGF isoforms in the development of vascular-targeted treatment strategies in soft tissue sarcoma. Poster presented at the British Microcirculation Society and Cell Adhesion Society Meeting. April, 2017. Birmingham, UK.
  • Thomas, R., Tozer, G. M. and Kanthou, C. Interactions neuropilin-1 and VEGF isoforms in the development of vascular-targeted treatment strategies in soft tissue sarcoma. Poster presented at the 30th Anniversary Symposium at the Rosetrees Trust. September, 2017. London, UK.

Presentations & Workshops

  • Thomas, R., Tozer, G. M. and Kanthou, C. The role of neuropilin-1 and VEGF isoforms in soft tissue sarcoma and their potential as predictive biomarkers of response to vascular-targeted therapies. Presentation given at The Medical School Annual Research Meeting at the University of Sheffield. June, 2017. Sheffield, UK.

Other

  • Ruth Thomas was awarded the second prize for the poster presentation at the 2017 30th Anniversary Symposium at the Rosetrees Trust.
    Project status: 
    open